Safety and Feasibility of a Mini-CVD/Methotrexate-Cytarabine Regimen With Induction Blinatumumab for Older and Frail Adults With Acute Lymphoblastic Leukemia: A Small Case Series From Brazil (SOHO 2026) - Sep 1, 2026 - Abstract #ALL-887; "Intervention: We report the first three cases treated with an approach similar to the MD Andersondesigned protocol for frail populations, with the omission of inotuzumab ozogamicin. Odd induction cycles consisted of the classic reduced-intensity CVD regimen, with rituximab 375 mg/m2 on day 1 for CD20-positive patients... Considering the challenges of treating older and frail adults with B-cell ALL, we demonstrated a promising approach with manageable toxicity that can be reproduced in private centers in Brazil and developing countries where blinatumomab is approved for first-line treatment. Additional data are needed to prove the efficacy of our approach. CD: cluster of differentiation, CNS: central nervous system, CVD: cyclophosphamide, vincristine, dexamethasone, MRD: minimal residual disease, Ph: Philadelphia chromosome, POMP: prednisone, vincristine (Oncovin), methotrexate, 6-mercaptopurine."
Clinical • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • CD20
|
|
Tali Scheinkman Band 1,2; Danilo O Tavares 2,3; Sylvia Dalcolmo 2,3; Mariana Guarana 2,4,3; Marcella Donato 3,5; Sophia Kilgore 3; Thais Barbosa Rodrigues 6; Angelo Atalla 6; Daniel G Tabak 2,3; Ruddy Dalfeor 2,3
|